New epilepsy drug RAP-219 enters final testing phase

NCT ID NCT07563881

Recruiting now Disease control Sponsor: Rapport Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called RAP-219 in 333 adults with focal seizures (a type of epilepsy). The goal is to see if the drug safely reduces how often seizures happen compared to a placebo. Participants must be 18-75, have had focal epilepsy for at least 2 years, and take 1-3 other seizure medicines.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPILEPSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

epilepsy focal epilepsy visual epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPILEPSY FOCAL EPILEPSY FOCAL SEIZURE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Amicis Research Center
RECRUITING

Palmdale, California, 91324, United States
Indiana University Health Fort Wayne Neurology
RECRUITING

Fort Wayne, Indiana, 46804, United States
Mid-Atlantic Epilepsy and Sleep Center
RECRUITING

Bethesda, Maryland, 20817, United States